Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus

Vandana Singh

July 27, 2026 5 min read

CRIS
-8.00%

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below.

On Wednesday, Curis Inc.announced updated positive clinical trial results for its investigational drug emavusertib, alongside expanded trial timeline guidance.

The biotechnology firm detailed key advances across its ongoing clinical programs evaluating the oral IRAK4 and FLT3 inhibitor for targeted blood cancers.

Analyst Adds CLL Valuation, Revises Launch Timelines

HC Wainwright wrote that TakeAim CLL enrollment is running ahead of plan, with consented patients rising to 10 and year-end guidance raised to 5-10 patients. The analyst views the December readout as the nearest-term value driver.

Don't Miss:

A single bad hire can set a startup back years. Here are the 5 hires founders most often misjudge — and why
Still Learning the Market? These 50 Must-Know Terms Can Help You Catch Up Fast

The firm reiterated the Buy rating on the stock and raised the price forecast from $17 to $43.

Analyst Sara Nik said the update adds a valuation for emavusertib in Chronic lymphocytic leukemia (CLL) following the launch of the TakeAim CLL study, assuming a 10% probability of success, $500 million in peak sales and a 2032 commercial launch.

The update also pushes the estimated launch for PCNSL to 2029 from 2028, reflecting management's timeline for completing enrollment by 2027 and the follow-up needed to support an accelerated approval filing.

Acute Myeloid Leukemia /Myelodysplastic Syndromes (AML/MDS) launch estimate was moved to 2032 from 2030, as further development depends on additional funding.

Upcoming Data Could Drive Further Upside

Nik said upside could come from upcoming data from the registrational PCNSL cohort, the initial CLL readout, and potential expansion into additional Non-Hodgkin Lymphoma (NHL) subtypes where BTK inhibitors are already used.

The management noted that duration of response (DoR) in BTKi-experienced patients is expected to exceed four to six months, with some patients on therapy for close to three years.

"Directionally, this is reassuring against what we view as the relevant regulatory bar for an ORR-based accelerated approval," Nik wrote in an investor note on Friday.

Image via Shutterstock/ Yomal2233

Read Next:

Skip the Regrets: The Essential Retirement Tips Experts Wish Everyone Knew Earlier.
Think you're saving enough for your kids? You might be dangerously off — see why

Building Wealth Across More Than Just the Market

Building a resilient portfolio means thinking beyond a single asset or market trend. Economic cycles shift, sectors rise and fall, and no one investment performs well in every environment. That's why many investors look to diversify with platforms that provide access to real estate, fixed-income opportunities, precious metals, and even self-directed retirement accounts. By spreading exposure across multiple asset classes, it becomes easier to manage risk, capture steady returns, and create long-term wealth that isn't tied to the fortunes of just one company or industry.

Arrived

Backed by Jeff Bezos, Arrived Homes makes real estate investing accessible with a low barrier to entry. Investors can buy fractional shares of single-family rentals and vacation homes starting with as little as $100 . This allows everyday investors to diversify into real estate, collect rental income, and build long-term wealth without needing to manage properties directly.

Realberry

Institutional-quality real estate has traditionally been difficult for individual investors to access. Realberry gives accredited investors direct access to private real estate opportunities backed by a team with 35 years of experience, $3.4 billion in assets under management, and $481 million in cumulative distributions paid to investors as of Q4 2025, according to the company. With a portfolio spanning 13 million square feet across seven U.S. states, Realberry focuses on acquiring, developing, and managing real estate with an emphasis on long-term value creation while its principals often invest alongside clients to help align interests.

FarmTogether

Farmland has historically held its value through market volatility and delivered returns uncorrelated to stocks and bonds. For accredited investors, FarmTogether offers direct access to high-quality U.S. farmland starting at $15,000 — fully managed, with no landlord headaches.

Immersed

Immersed is building technology for the future of work through spatial computing. Known for its AR/VR productivity platform that enables users to work across multiple virtual screens, the company has grown to more than 1.5 million users worldwide. Immersed is also developing Visor, a lightweight headset designed specifically for professional productivity, positioning the company at the intersection of remote work, extended reality (XR), and next-generation computing.

Fundrise

Private real estate and private credit can add income and stability to a stock-heavy portfolio. Fundrise offers access to diversified private real estate and credit strategies through an easy-to-use platform, with professionally managed portfolios designed to generate passive income and long-term growth.

Mode Mobile

Mode Mobile is changing the way people interact with their phones by letting users earn money from the same apps and activities they already use every day. Instead of platforms keeping all the advertising revenue, Mode Mobile shares a portion back with users who engage with content, play games, and scroll on their devices. Named one of Deloitte's fastest-growing software companies in North America, the company has built a large beta user base and is scaling a model that turns everyday smartphone usage into a potential income stream.